Enhanced expression of the CD38 membrane protein has also been reported in other aggressive hematological malignancies, including chronic lymphocytic leukemia (CLL), T-cell acute lymphoblastic leukemia (T-ALL), diffuse large B-cell lymphomas (DLBCL), and T and NK lymphomas (NKTL) [13,14,15,16,17]. This evidence concerns the gene CD38 and diffuse large B-cell lymphoma.